Objective To investigate the efficacy of vericiguat combined with sacubitril valsartan sodium in the treatment of chronic heart failure(CHF)and its impact on electrocardiogram parameters and the incidence of clinical endpoint events.Methods A total of 104 patients with CHF admitted to Luzhou People's Hospital from June 2022 to January 2024 were selected and divided into the control group(n=52)and the combination group(n=52)using the randomized numerical table method.The patients in the control group were treated with sacubitril valsartan sodium and those in the combination group with vericiguat and sacubitril valsar-tan sodium.All the 104 patients were treated for 3 months.The therapeutic effects,electrocardiogram parameters(QRS interval,Te-Tp interval and heart rate(HR)),left ventricular ejection fraction(LVEF),N-terminal pro B-type natriuretic peptide(NT-proBNP),and the incidence of clinical endpoint events were observed and compared between the two groups.Results The total effective rate in the combined group was 94.23%(49/52),which was higher than that of 80.77%(42/52)in the control(χ2=4.308,P＜0.05).After treatment,the QRS interval and Te-Tp interval were significantly higher in the combined group than in the control((97.75±10.62)ms vs(66.52±11.37)ms,(106.34±10.86)ms vs(84.48±13.69)ms)(t=4.078,7.278,both P＜0.001).The HR was(73.41±8.13)beats·min-1 in the combined group and(75.54±8.26)beats·min-1 in the control group,showing no statistically significant difference(t=1.325,P＞0.05).The LVEF and NT-proBNP were(46.35±7.49)%and(1 120.57±81.69)pg·mL-1,in the combination group and(52.47±7.87)%and(1 338.62±84.73)pg·mL-1 in the control group,demonstrating that the differences were statistically significant(t=4.062,13.360,both P＜0.001).The total incidence of clinically focused events in the combined group was 13.46%(7/52),which was remarkably lower than that of 26.92%(14/52)in the control(χ2=7.675,P＜0.05).Conclusion Compared to treatment with sacubitril valsartan sodium alone,the combined treatment with vericiguat and sacubitril valsartan sodium is more effective in treating CHF.The latter can effectively im-prove electrocardiogram parameters,increase LVEF and NT-proBNP levels and reduce the incidence of clinical endpoint events.
维普
万方数据